TP53 mutations have been reported in 8% of all AML cases, 4.3% of de novo AML, 16.7% of secondary AML, 25–45% of post-myeloproliferative neoplasm AML (MPN-AML) and 70% of AML with complex karyotype AML [20,21,22,23,24]. The gene discussed is TP53; the disease is myeloproliferative disorder.